• Journal of Microbiology and Biotechnology
• /
• 제26권2호
• /
• pp.402-407
• /
• 2016

Lactic acid bacteria have been identified to be effective in reducing cholesterol levels. Most of the mechanistic studies were focused on the bile salt deconjugation ability of bile salt hydrolase in lactic acid bacteria. However, the mechanism by which Lactobacillus decreases cholesterol levels has not been thoroughly studied in intact primate cells. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) is the vital enzyme in cholesterol synthesis. To confirm the effect of probiotic Lactobacillus strains on HMGCR level, in the present study, human hepatoma HepG2 cells were treated with Lactobacillus strains, and then the HMGCR level was illustrated by luciferase reporter assay and RT-PCR. The results showed that the level of HMGCR was suppressed after being treated with the live Lactobacillus strains. These works might set a foundation for the following study of the antihyperlipidemic effects of L. acidophilus, and contribute to the development of functional foods or drugs that benefit patients suffering from hyperlipidemia diseases.

• Food Science and Biotechnology
• /
• 제16권4호
• /
• pp.584-589
• /
• 2007

The effect of water extract of adzuki beans on acetaminophen-altered lipid metabolism was examined in rats. Control group of rats was fed a basal diet, another group of rats was fed 0.5% acetaminophen (APAP group), and a third group of rats was fed 0.5% acetaminophen plus 5% adzuki bean extract (ABE group) for 4 weeks. Serum total and HDL cholesterol levels in the APAP group were significantly lower than those in the control and ABE groups. Hepatic cholesterol $7{\alpha}-hydroxylase$ and fatty acid synthase mRNA levels in the APAP and ABE groups were significantly higher and lower than in the control group, respectively. Hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA level in the APAP group was significantly lower than in the control group, whereas that in the ABE group was significantly higher than in the APAP group. These results indicate that adzuki bean extract may improve the acetaminophen-altered serum lipid metabolism in rats.

• Applied Biological Chemistry
• /
• 제41권1호
• /
• pp.47-52
• /
• 1998

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 환원효소는 식물의 병원균 방어물질 (phytoalexin), 광합성 색소 (the phytol of chlorophyll), 성장 호르몬 (abscisic acid와 gibberellin 등) 및 스테롤 (phytosterol) 등의 생합성에 관여하는 주효소이다. 암조건 하에서 발아 후 4일째의 벼 유묘 microsome을 재료로 비이온성 detergent 인 Brij W-1 (final 0.4%)을 사용하여 가용화 시킨 후, DEAE-Sephadex A-50 크로마토그래피 칼럼과 hexaneagarose를 matrix로 기질인 HMG-CoA를 결합시켜 제조한 친화성 크로마토그래피 칼럼을 이용하여 세포막 결합효소인 HMG-CoA 환원효소를 정제하였다. 정제된 HMG-CoA 환원효소의 최종 회수율은 7.14% 였고, 분자량은 10% SDS-PAGE에서 55 kDa이였다 HMG-CoA 환원효소의 최적 반응 온도는 $37^{\circ}C$, 최적 반응 pH는 6.9였고, 기질인 HMG- CoA에 대한 HMG-CoA 환원효소의 $K_m$ 및 $V_{max}$ 값은 $180\;{\mu}M$과 107 pmol/mg, 수소공여체인 NADPH에 대한 $K_m$과 $V_{max}$값은 $810\;{\mu}M$과 32.1 pmol/min/mg이였다.

• Journal of the Korean Wood Science and Technology
• /
• 제32권1호
• /
• pp.17-27
• /
• 2004

식용 임산자원인 산채류를 기능성 식품으로 개발하고자 산마늘을 비롯한 총 13종의 에탄올 조추출물에 대한 콜레스테롤 저하활성을 검정하였다. 즉, 콜레스테롤 생합성 과정 초기에 관여하는 3-hydroxy-3-methylglutaryl coenzyme A reductase(HMG-CoA reductase)와 후기에 관여하는 squalene synthase의 효소 활성을 조사한 결과 산마늘 잎 에탄올 추출물이 두 효소의 활성을 공히 70% 이상 저해하여 활성이 가장 우수한 것으로 나타났다. 그리고 이러한 콜레스테롤 저하활성과 관련이 있는 물질을 탐색하고자 산마늘로부터 물질 단리를 시도하여 디클로로메탄 가용부로부터 kaempferol과 quercetin을 단리하였다. 또한 유전자 레벨에서의 콜레스테롤 저하 활성을 조사하기 위해 단리물질과 분획물을 C100세포(햄스터 유래 HMG-CoA reductase 고발현 세포주)에 각각 5 ㎍/㎖과 10 ㎍/㎖로 24시간 처리하여 HMG-CoA reductase와 squalene synthase의 mRNA 발현 정도를 조사하였다. 그 결과 10 ㎍/㎖로 kaempferol과 quercetin을 처리한 경우 두 효소의 mRNA가 전혀 발현하지 않는 것으로 나타나 유전자 레벨에서의 콜레스테롤 생합성 저해 효과를 확인할 수 있었다. 이상의 결과 산마늘 잎 에탄올 추출물은 콜레스테롤 생합성에 관여하는 HMG-CoA reductase와 squalene synthase의 활성을 저해하며 이러한 활성 저해 효과는 kaempferol과 quercetin에 기인하는 것으로 사료되었다. 특히 kaempferol과 quercetin은 여러 식물의 성분으로서 이미 알려진 화합물이지만 콜레스테롤 저하활성이 있는 것으로 밝혀진 것은 이번이 처음으로 금후 이들 물질과 이들 물질을 함유하고 있는 식물 활용에 필요한 자료를 제공하였다고 사료된다.

• BMB Reports
• /
• 제40권6호
• /
• pp.861-869
• /
• 2007

The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR; EC1.1.1.34) catalyzes the first committed step of isoprenoids biosynthesis in MVA pathway. Here we report for the first time the cloning and characterization of a full-length cDNA encoding HMGR (designated as CgHMGR, GenBank accession number EF206343) from hazel (Corylus avellana L. Gasaway), a taxol-producing plant species. The full-length cDNA of CgHMGR was 2064 bp containing a 1704-bp ORF encoding 567 amino acids. Bioinformatic analyses revealed that the deduced CgHMGR had extensive homology with other plant HMGRs and contained two transmembrane domains and a catalytic domain. The predicted 3-D model of CgHMGR had a typical spatial structure of HMGRs. Southern blot analysis indicated that CgHMGR belonged to a small gene family. Expression analysis revealed that CgHMGR expressed high in roots, and low in leaves and stems, and the expression of CgHMGR could be up-regulated by methyl jasmonate (MeJA). The functional color assay in Escherichia coli showed that CgHMGR could accelerate the biosynthesis of $\beta$-carotene, indicating that CgHMGR encoded a functional protein. The cloning, characterization and functional analysis of CgHMGR gene will enable us to further understand the role of CgHMGR involved in taxol biosynthetic pathway in C. avellana at molecular level.

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2002년도 생물공학의 동향 (X)
• /
• pp.184-187
• /
• 2002

Lovastatin is a cholesterol-lowering agent, which plays a role of an inhibitor of 3-hydroxy-3- methylglutaryl coenzyme A reductase (HMG-CoA). When thiamine was supplemented in 3L batch fermentation, the production of lovastatin was improved. At the same time, the levels of pyruvic acid and NAD(P)H were estimated in the course of the fermentation of A. terreus. For the high level production of lovastatin, semi fed-batch fermentation was performed. And the thiamine level was maintained to a concentration of 20 mg/L and glucose was supplied. The final dry cell weight was lowered by 30 % and final lovastatin concentration was increased by 33 %. Final lovastatin concentration of 3.3 g/L was achieved in 8 days.

• 한국식품영양학회지
• /
• 제15권4호
• /
• pp.307-313
• /
• 2002

체내 cholesterol 수치를 낮추기 위하여 HMG-CoA reductase 활성을 저해하는 물질들을 닭에게 급여하여 in vitro상에서 검토한 결과, HMG-CoA reductase 활성에 대한 마늘, lovastatin과 copper의 순으로 저해능은 51.3%, 87.5%, 82.0%이었다. 또한 혈장, 가슴조직, 간장의 cholesterol 함량에 대한 마늘(3% in diet), lovastatin(300mg/Kg of diet), copper(200mg/Kg of diet)의 효과를 검토하였다. 혈장 중의 cholesterol 함량과 HDL, LDL cholesterol 함량은 3% 마늘의 투여로 감소되어졌으나 copper의 투여는 오히려 증가하였고, lovastatin 투여에 의한 차이는 나타나지 않았다. 그리고 간장과 가슴조직의 cholesterol과 triglyceride는 사료에 cholestrol의 수치를 저하시키는 물질을 첨가하였으나 별다른 차이가 없었다.

• Food Science and Biotechnology
• /
• 제14권4호
• /
• pp.514-517
• /
• 2005

Abilities of Korean black raspberry (KBR) wine to induce differentiation of 3T3 L1 adipocytes and express HepG2 cardiovascular disease-related genes were determined and compared with those of red wine. Red wine attenuated the differentiation of adipocytes faster than KBR wine and control. KBR wine decreased cholesterol concentration in HepG2 cells at a similar level to that of red wine, resulting in similar degrees of suppression in apolipoprotein B100, and enhancement in LDL receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels.

• Biomolecules & Therapeutics
• /
• 제16권1호
• /
• pp.28-33
• /
• 2008

Atorvastatin calcium salt (1) was obtained through the preparation of lactone compound (8) from 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-ethyl)-2-phenyl-1,3,2-dioxaborinan-4-yl)acetic acid tert-butyl ester (9) by hydrolysis in basic condition. Efficient hydrolysis of boronate compound 9 aimed at the viable synthesis for commercial production and purification of Atorvastatin calcium is reported. Detail studies of evaluation procedure are also reported.

• 약학회지
• /
• 제53권4호
• /
• pp.206-216
• /
• 2009

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Statins) are potent inhibitors of cholesterol biosynthesis. Cholesterol-lowering therapy using statins significantly reduces the risk of coronary heart disease. Various discovery of statins as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers. In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-2 (BMP-2)-mediated osteoblast expression. Clinical and animal test results of statins focusing on the prevention and treatment of bone fractures was collected. Three independent literature searches were performed by using from January 1, 2002 to September 2008 for clinical and animal test results. Search term included statins, HMG-CoA reductase inhibitors, pleiotropic effects, fracture, osteoporosis and clinical and animal test. No consensus has been reached whether clinical use of statins has beneficial effects on bone health, partly due to lower statin concentrations because of first-pass metabolism by the liver. Experimental use of statins as stimulators of bone formation suggests that they may have widespread applicability in the field of orthopaedics. With their combined effects on osteoblasts and osteoclasts, statins have the potential to enhance resorption of synthetic materials and improve bone ingrowth. In conclusion, The use of statins in the prevention and treatment of bone fractures requires further study. But observational studies suggest that statins for decreasing bone fractures including osteoporosis have to be considered local direct administration like transdermal or subcutaneous type over oral adminstration.